Curative Biotechnology Inc (CUBT)

[Eagle1]

CTYX DD Packet with hyper links!

http://tinyurl.com/curativebiodd

Connectyx (OTC PINK: CTYX)

[Soon to be Curative Biotechnology (OTC PINK: CURB) Q1 2021]
Company Background

Corporate Overview presentation
Mission and business plan: Fulfill unmet needs of patients with rare diseases by seeking opportunities through collaboration, partnerships, and co-development of pharmaceuticals (orphan drugs) and medical devices. “We plan to build our portfolio of rare disease therapeutics principally based on collaborations and licenses with both academic and corporate partners.”
Updated Mission: To develop therapeutics, medical devices, or diagnostics at an accelerated pace to fulfill the unmet needs of patients with rare diseases. We focus on identifying, in licensing and developing disease modifying therapeutic drug candidates with a focus on rare disease indications.
Team
Paul M. Michaels (CEO), Barry A. Ginsberg (CSO), Pam Bisikirski (Director of Communications), Michael K. Fish (Chairman of the Audit Committee of the Board).
SAB: Michael Grace, Ph.D. [1], Ronald Bordens, Ph.D. [1], and I. Richard Garr, Esq. [2]
1/27/2020: FL Dept of State Amendment and Restated Articles confirming company name change and securities details.
11/23/2020: Company name change to Curative Biotechnology, Inc. (FL Dept of State entity) and ticker to $CURB during Q1 2021 pending FINRA approval. Secured non-dilutive bridge financing. Transitioning to a fully reporting company. Corporate website change in progress from connectyx.com to curativebiotechnology.com (domain created 11/10/2020).
4/13/2020: Extinguished convertible debt, which led to net income in April 2020 and decreasing fully diluted shares outstanding. Returned to OTC Pink Current status with new business.
3/6/2020: Reverse merger between SunMed Advisors, LLC and Connectyx, keeping the shell’s name and ticker, $CTYX. NOTE: The prior CEO and business had a dark history, but NOTHING to do with the new business. Legacy and new business are completely separate.
Licenses, Developments, and Pipeline

Metformin for therapeutic treatment of retinal degenerative disease (NIH license):
2/4/2021: Company received grant of license from NIH for repurposing metformin to treat degenerative eye disease.
10/22/2020: Company requested a prospective grant of an Exclusive Patent License from the NIH to develop metformin to treat retinal degenerative diseases (worldwide territory). Comments to the NIH were due by 11/6/2020.
Patent rights currently assigned and/or exclusively licensed to the US government:
U.S. provisional patent application No. 62/899,899 and entitled, “Druggable Targets to Treat Retinal Degeneration” filed September 13, 2019 (E-227-2017-US-01)
International Patent Application No.: PCT/US2020/050540 and entitled, “Druggable Targets to Treat Retinal Degeneration” filed September 11, 2020 (E-227-2017-PCT-02)
KEI submitted comments to NIH [5][6] expressing concerns.
Monoclonal antibody to treat pediatric glioblastoma (NIH license):
10/16/2020: Company received grant of license from the NIH for use of Novel Monoclonal Antibody to treat glioblastoma (worldwide territory).
Licensed patent rights granted to $CTYX:
US Patent No. 10,548,987 was issued in Feb 2020 E-221-2015-0-US-03
8/28/2020: Company requested a prospective grant of an Exclusive Patent License from the NIH to use an Anti-CD56 drug conjugate to target pediatric glioblastoma (E-221-2015E). Comments to NIH were due by 9/14/2020.
Patent rights currently assigned and/or exclusively licensed to the US government:
(Was not mentioned in 10/16 PR) PCT/Application No. PCT/US2016/044777 filed in July 2016 E-221-2015-0-PCT-02
(Was not mentioned in 10/16 PR) U.S. Provisional Patent Application No. 62/199,707 filed July 2015 E-221-2015-0-US-01
Historical non-issue: KEI and UACT submitted comments to NIH [3][4] expressing concerns with previous management of the company, NOTHING to do with the new business.
Rabies treatment (MABT license):
11/23/2020: 11/23 PR implies IMT504 rabies license deal is complete.
10/9/2020: Company Announces Definitive Agreement with Mid-Atlantic BioTherapeutics, Inc. for Treatment of Symptomatic Rabies.
Rabies qualifies for a Priority Review Voucher (PRV) under the Tropical Disease Priority Review Voucher Program.
PRVs can be used or sold to other companies (potential $125 million to $200 million value and non-dilutive financing) to expedite FDA review on any drugs/vaccines, not just rare disease drugs/vaccines.
See an interactive PRV diagram created by Duke University for status on past awarded PRVs.
Company will acquire all necessary worldwide rights for development of IMT504 to treat symptomatic rabies. IMT504 was granted orphan drug designation in the US. Transaction expected to close by 10/26/2020 based on 8/27/2020 PR.
“IMT504 is our [Mid-Atlantic BioTherapeutic, Inc (MABT)] proprietary, patented technology platform with over $23 Million invested in research. Our technology platform creates a very rapid, safe and effective immune system response.“
Note: A different company (NidoVax) already partnered with MABT to develop a vaccine with IMT504 for COVID-19.
Security Details

OTC Markets Security Details
Published by Google Drive–Report Abus